564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents

• Ke Liu,
• Christine Bonzon,
• Seung Chu,
• Rumana Rashid,
• Umesh Muchhal,
• John Desjarlais,
• Matthew Bernett,
• Nicole Rodriguez,
• Nargess Hassanzadeh-Kiabi,
• Connie Ardila

Affiliations

Ke Liu

Aff1 grid.417587.80000000122433366Office of Cellular, Tissue, and Gene Therapies (OCTGT)Center for Biologics Evaluation and Research (CBER) Rockville MD USA

Christine Bonzon

Aff390 Xencor, Inc. Monrovia CA USA

Seung Chu

Aff390 Xencor, Inc. Monrovia CA USA

Rumana Rashid

Aff390 Xencor, Inc. Monrovia CA USA

Umesh Muchhal

Aff390 Xencor, Inc. Monrovia CA USA

John Desjarlais

Aff390 Xencor, Inc. Monrovia CA USA

Matthew Bernett

Xencor, Inc., MONROVIA, CA, USA

Nicole Rodriguez

Xencor, Inc., MONROVIA, CA, USA

Nargess Hassanzadeh-Kiabi

Xencor, Inc., MONROVIA, CA, USA

Connie Ardila

Xencor, Inc., MONROVIA, CA, USA